Part 1. Overview Information

Key Dates

All applications are due by 5:00 PM local time of applicant organization. 

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from NIH Guide for Grants and Contracts).

Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

1. Use the NIH ASSIST system to prepare, submit and track your application online.
2. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.
   
   
3. Use Grants.gov Workspace to prepare and submit your application and eRA Commons to track your application.



Table of Contents
Part 1. Overview Information
Key Dates
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Complex and challenging research questions benefit from the integrated efforts of teams/labs employing complementary approaches with multiple areas of expertise. Team-based efforts can converge on high-impact discoveries, such as creating new disciplines, resolving longstanding or intractable problems, or defining new areas that challenge existing paradigms.

This funding opportunity announcement (FOA) encourages Collaborative Program Grant applications from institutions/organizations that propose projects addressing complex and challenging biomedical problems within the mission of NIGMS. Multidisciplinary research teams must have a highly integrated approach for each of their project goals. The Collaborative Program Grant is designed to support research in which funding a team of interdependent investigators to achieve a unified scientific goal offers significant advantages over supporting individual research project grants.

Features of successful applications include:

• Each PD/PI is committed to team science and willing to devote a major part of their research effort to the team project.
• Achieving the goal(s) requires a team approach.
• Each biological question posed requires a cohesive team with an integrated approach.
• A team management structure is developed for achieving program goals.

NIGMS recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from, research and enhancing public trust. To support the best science, NIGMS encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to:

• Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based).
• Individual applications and partnerships that enhance geographic and regional engagement.
• Investigators and teams composed of researchers at different career stages.
• Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women.
• Project-based opportunities to benefit early- and mid-career investigators. 

This FOA requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application (see Section IV.2 SF424(R&R) Other Project Information. Other Attachments). For further information on the Plan for Enhancing Diverse Perspectives (PEDP), please see https://braininitiative.nih.gov/about/pedp-key-elements-and-examples.

Applications may address any area of science within the NIGMS mission. NIGMS supports generalizable, foundational basic research that increases understanding of biological processes at a range of levels, from molecules and cells, to tissues, whole organisms, and populations. NIGMS also supports research in a limited number of clinical areas that affect multiple organ systems. Truly new interdisciplinary ideas for approaching significant biological problems are encouraged. Applications that bridge the research interests of more than one area of science supported by NIGMS are also encouraged but must remain within the NIGMS mission.

Research with the overall goal of gaining knowledge about a specific organ or organ system, or the pathophysiology, treatment, or cure of a specific disease or condition will, in most cases, be more appropriate for another Institute or Center. Consultation with NIGMS staff (see below) prior to preparing an application is strongly encouraged.

Projects outside the NIGMS mission will be rejected without review.

Applicants for smaller projects with one or two PD/PIs should consider submitting a multi-PD/PI application to the "NIH Research Project Grant (Parent R01)" FOA (see the Parent Announcement website for the current issuance of that FOA), or if they are current NIGMS R35 MIRA awardees, they could consider collaborating as part of the 51% research effort on their current R35 award (note they will not receive additional funds from the RM1).

Applications that are mainly focused on the creation, expansion, and/or maintenance of community resources, or on infrastructure development, are not appropriate for this FOA. Although Collaborative Program Grants may include some technology development, applications with a central focus on the creation of new technologies would not be considered for funding as a Collaborative Program Grant and are more appropriate for the other NIGMS mechanism for funding technology research and resources.

Applications that employ specific cells or tissues to address a fundamental biomedical question are appropriate. However, applications that focus solely on a specific organ or disease state and that are within the mission areas of other NIH Institutes and Centers would not be appropriate for this FOA.

Research involving human subjects is permitted in the Collaborative Program Grant. Clinical research must be completely within the context of the NIGMS clinical areas (anesthesiology, clinical pharmacology, sepsis, injury, and critical illness). Mechanistic clinical trials are permitted when the mechanistic study is an essential part of the research program. Clinical trials that are designed to test safety and efficacy of interventions (Phase I, Phase II, Phase III) for the purpose of future clinical treatment and/or regulatory approval are not permitted. Potential applicants are encouraged to confer with the NIGMS Scientific/Research staff (in Section VII. Agency Contacts of this FOA) before submitting an application that includes clinical research. NIGMS does not intend to fund applications that contain clinical research within the missions of other Institutes and Centers at NIH or other federal agencies.

Program Organization

Applications submitted to this FOA are expected to propose a single, well-integrated research plan of sufficient scope, complexity, and impact to justify the investment of significant resources. Applicants are expected to describe a cohesive program with a single set of specific aims sufficient to accomplish program objectives that can be achieved within a maximum of ten years (one five-year program with one five-year competitive renewal). Program objectives that are not likely to be achieved within ten years are not appropriate for this FOA.

Applications that propose extrapolations of a single line of research or propose parallel but independent advancement of different areas are not appropriate for this FOA.

Applicant teams should be nimble to incorporate new knowledge and techniques to achieve program objectives and tackle unanticipated challenges. The application may include early-stage investigtor (ESI)-led development projects in future years to investigate new, but related, lines of research.

Team Management and Optional Activities

An RM1 must be a multiple PI application. Therefore, applicants must include a MPI leadership plan as required by the NIH. In addition, applications are expected to develop a comprehensive team management plan that addresses the following:

• Appropriate organizational structure and team composition
• Shared leadership, contributions, and distributed responsibility for decision making
• Resource allocation
• Plans for professional development
• Conflict resolution

Applicants may wish to address how they will develop trust and a shared vision, as well as how shared responsibilities, interpersonal interactions, and professional credit will be managed. Additionally, applicants may consider a scientific project manager or program coordinator as part of the management plan.

Collaborative Program Grant applications may propose the use of optional future year developmental funds to support ESIs at domestic institutions whose availability was unknown and/or who can bring new ideas and expertise to the program that was not initially conceived to be relevant at the time of application. Developmental funds are in addition to the base grant budget and will be made available after the first year of the award, subject to NIGMS staff approval and availability of funds. See Section VI. Award Administration Information. Prior Approval for Use of Developmental Funds.

The proposed new work that ESIs will pursue must be well aligned with the aims of the original grant.

If the application requests developmental funds for studies directed by ESIs, plans must be included for selecting the ESIs and for leveraging existing resources for appropriate mentoring, including the effective conduct of multidisciplinary team science, as described in Part 2. Section IV.2 of this FOA.

ESIs supported by developmental funds will be able to seek and receive independent funding. A review criterion and funding consideration for any subsequent Renewal application will be evaluation of the outcomes of the ESI mentoring and support, including whether ESIs successfully obtained independent funding. Note that a plan for the use of developmental funds to support ESIs is an optional activity.

Prior Consultation with IC staff

NIGMS intends to fund a limited number of applications. Therefore, consultation with relevant staff at least 10 weeks prior to the application due date is strongly encouraged. Once applicants have identified overall program objectives and PD/PI participants, NIGMS staff may be able to advise applicants whether the proposed research strategy meets the goals and mission of the Institute, whether it addresses one or more high priority research areas, and whether it is appropriate for a Collaborative team program. A collaborative program that is closely related to the goal of a PD/PI's existing NIGMS-funded research might require that funding be relinquished to avoid scientific overlap. Institute staff will not evaluate the technical and scientific merit of the proposed program in advance; technical and scientific merit will be determined during peer review using the review criteria indicated in this FOA. During the consultation phase, if the proposed research strategy does not meet NIGMS' programmatic needs, is not appropriate as a Collaborative Program Grant, or is outside the NIGMS mission, applicants will be encouraged to consider other funding opportunities. 

See Section VIII. Other Information for award authorities and regulations.

Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs.

Section II. Award Information

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.

Section III. Eligibility Information

1. Eligible Applicants

Higher Education Institutions

• Public/State Controlled Institutions of Higher Education
• Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

• Hispanic-serving Institutions
• Historically Black Colleges and Universities (HBCUs)
• Tribally Controlled Colleges and Universities (TCCUs)
• Alaska Native and Native Hawaiian Serving Institutions
• Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

• Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
• Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

• Small Businesses
• For-Profit Organizations (Other than Small Businesses)

Local Governments

• State Governments
• County Governments
• City or Township Governments
• Special District Governments
• Indian/Native American Tribal Governments (Federally Recognized)
• Indian/Native American Tribal Governments (Other than Federally Recognized)

Federal Governments

• Eligible Agencies of the Federal Government
• U.S. Territory or Possession

Other

• Independent School Districts
• Public Housing Authorities/Indian Housing Authorities
• Native American Tribal Organizations (other than Federally recognized tribal governments)
• Faith-based or Community-based Organizations
• Regional Organizations

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 

Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

• System for Award Management (SAM)– Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
  • NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
  • Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.
• eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants.gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
• Grants.gov – Applicants must have an active SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support. See, Reminder: Notice of NIH's Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities, NOT-OD-22-019.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

The application is required to be submitted as a multiple PD/PI application, with three to six PDs/PIs. All PDs/PIs must have an appointment at a domestic institution. Scientists employed solely by foreign institutions may not serve as one of the PDs/PIs of the multiple PD/PI team, although they may be included in the application as collaborators/co-investigators, consultants, or other significant contributors. See the multiple PD/PI Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide, and the Grant Policy Statement on Multiple Principal Investigators. Minimum allowed efforts by the PDs/PIs are described in the R&R Budget instructions in Part 2. Section IV.2.

Any eligible scientists with the interest and ability to develop a team science program to address an important research question are welcome to apply.

• NIGMS encourages the participation of early career investigators as part of the multiple PD/PI team as appropriate.
  • Note that ESIs and new investigators who participate as a PD/PI will lose their ESI or new investigator status for future NIH applications.
  • ESIs supported by developmental funds in future years are not designated as PDs/PIs and will not lose ESI status.
• PDs/PIs who have an active NIGMS R35 award can participate as a RM1 PD/PI. Their RM1 effort will be part of the 51% research effort on their current R35 award but may not receive additional funds .
• Applicants with substantial unrestricted research support may receive funding from this award as their one NIGMS grant award, or may participate in an unfunded advisory or consulting role without loss of their ability to receive one funded NIGMS grant, consistent with NIGMS funding policies.

2. Cost Sharing

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

3. Additional Information on Eligibility

Number of Applications

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Two applications per institution (with a Unique Entity Identifier ) and a unique NIH eRA Institutional Profile File (IPF) number) are allowed per review round. The same or a similar topic may be submitted for subsequent review rounds involving the same or a similar team, but must be presented as a New application, not a Resubmission.

Applications that are not considered to be within the NIGMS mission will not be reviewed. Eligibility and appropriateness to the NIGMS mission will be evaluated again after review and prior to funding. Applications outside the NIGMS mission will not be funded. Given that only two applications are permitted per institution per review round, it is important to contact NIGMS staff before committing to any particular team and its topic area.

Section IV. Application and Submission Information

1. Requesting an Application Package

The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Letter of Intent  

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

• Descriptive title of proposed activity
• Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
• Names of other key personnel
• Participating institution(s)
• Number and title of this funding opportunity

The letter of intent should be sent to:

Email: RM1mailbox@nigms.nih.gov

Page Limitations

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed along with the following page limitations for the Research Strategy:

The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.

Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H application forms packages.

SF424(R&R) Cover

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Other Project Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Facilities and Other Resources: Describe aspects of the institutional environment that support team science. Describe the institutional and regional research resources that will be utilized to accomplish the goals of the program. Describe how access to these resources will be ensured for team members.

Other Attachments: The following attachments must be included in the application:

Plan for Enhancing Diverse Perspectives (PEDP) (1 page maximum): The application must include a summary of strategies to advance the scientific and technical merit of the proposed project through expanded inclusivity. The PEDP should provide a holistic and integrated view of how enhancing diverse perspectives is viewed and supported throughout the application and can incorporate elements with relevance to any review criteria (significance, investigator(s), innovation, approach, and environment) as appropriate. Where possible, applicant(s) should align their description with these required elements within the Research Strategy section. The PEDP will vary depending on the scientific aims, expertise required, the environment and performance site(s), as well as how the project aims are structured. The PEDP should include a timeline and milestones for relevant components that will be considered as part of the review. Examples of items that advance inclusivity in research and may be part of the PEDP can include, but are not limited to:

• Discussion of engagement with different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based).
• Description of any planned partnerships that may enhance geographic and regional diversity.
• Plan to enhance recruiting of women and individuals for groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce.
• Proposed monitoring activities to identify and measure PEDP progress benchmarks.
• Plan to utilize the project infrastructure to support diverse junior, early- and mid-career researchers.
• Description of any training and/or mentoring opportunities available to encourage participation of students, postdoctoral researchers and co-investigators from diverse backgrounds.
• Publication plan that enumerates planned manuscripts and proposed lead authorship.
• Outreach and planned engagement activities to enhance recruitment of individuals from diverse groups as research participants including those from under-represented backgrounds.

For further information on the Plan for Enhancing Diverse Perspectives (PEDP), please see https://braininitiative.nih.gov/about/pedp-key-elements-and-examples.

This attachment should be titled “Plan for Enhancing Diverse Perspectives.”  

SF424(R&R) Senior/Key Person Profile

All instructions in the SF424 (R&R) Application Guide must be followed.

Inclusion of a scientific project manager or coordinator as a Senior/Key Person with adequate authority is recommended.

R&R Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

A single integrated application budget must cover all aims, personnel, equipment, resource assignments, and other costs of the program, with subcontracts as necessary.

Research Budget: To be successful, programs of this level of complexity are expected to require significant effort from all PDs/PIs involved. The contact PD/PI is required to devote at least 30% of their total research effort to this award, while other PDs/PIs are required to devote at least 25% of their total research effort to this award. The total research effort should :

• Include the PD/PI's combined research effort at all institutions where the PD/PI holds an appointment,
• Be expressed in person-months, and
• Not include time expended toward teaching and administration not directly related to the PD's/PI's research, and/or clinical duties

NIGMS staff will verify that the research effort requirements are met by using the Other Support documentation and will exclude support for which the purpose is education, training, or enhancing workforce diversity.

Certain supporting functions such as animal research costs and clinical research costs may be requested . Within the research budget, equipment - including data sharing and management systems, can be included if well justified. These costs must be included within the $1.5 million budget cap for direct costs. Equipment that duplicates existing institutional or regional shared facilities that are available to investigators must be identified and the proposed duplication should be well justified. Applicants should consider the need to ramp-up programs of this complexity and propose annual budgets accordingly. Do not request inflationary increases in the overall budget or in any of the individual budget categories. Changes in budget should reflect changes in activities required by the science.

PEDP Implementation Costs: Budget request may include allowable costs (as outlined in the Grants Policy Statement) associated with PEDP implementation. 

Optional Activities: Applicants may request additional developmental funds up to $250,000 direct costs in years 2-5 to support the addition of ESIs to the project team. These projects should incorporate new knowledge and techniques that were not anticipated in the application to achieve program objectives and to tackle unanticipated challenges. Such investigators should not have been available and obviously relevant at the time of application, and the work that they will lead should not overlap with the on-going funded work led by other team members. . Developmental funds may be used to support ESIs for up to three years. ESIs not at the applicant institution may be supported by subcontracts. Multiple ESIs may be supported sequentially or in parallel within the overall $250,000 direct costs budget (not including subcontract F&A). Development funds may not be used to provide direct funds for training, mentoring, or alterations and renovations.

R&R Subaward Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Cover Page Supplement

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Research Plan

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

Research Strategy: The Research Strategy must consist of the following two subsections, uploaded as a single pdf attachment with two major section headings:

A. Research Program

B. Team Management Plan and Optional Activities

A. Research Program: The proposed research should be presented as an integrated scientific program with a single set of specific aims organized to address the overall objectives rather than individual PD/PI contributions. The application should describe:

• The biomedical problem being addressed
• the significance of the project within the relevant scientific field(s);
• how successful accomplishment of the goals would provide substantial scientific advances;
• How the Collaborative Program Grant will enable the applicants to challenge or significantly advance existing paradigms;
• How the project will overcome long-standing bottlenecks to substantial progress, and/or develop new synergies between different scientific fields.
• Justification for a larger-scale collaborative approach and why the goals of the program could not be accomplished by other means.
• Innovative solutions to existing challenges.

The long-term goals of the proposed research should be achievable within a ten-year timeframe. The objectives for the first five years should be clearly defined. If a Renewal application is anticipated for a second, five-year period, longer-term, ten-year objectives should be included, and should clearly be identified as goals that extend beyond the current work plan. A process for deciding whether to submit a Renewal application should be included. The criteria for the decision to submit should include achievement of milestones or objectives, and the significance of the work proposed in the Renewal. Note that significant accomplishments are expected within the first five years of funding, regardless of whether the applicants plan to renew. Renewals beyond ten years of support will not be allowed.

The Research Program section should:

• Describe the underlying premise and scientific foundation of the project, experimental rationale, approaches, and steps taken to assure scientific rigor, with attention to the reasons a team science approach is required.
• Describe critical research milestones and any innovative aspects of the approach, including those arising from collaborative interactions.
• Justify any plans for technology development or new data sharing and archiving resources that are necessary to achieve program goals.

Shared resources that are needed to achieve project objectives should be integrated into the research plan. The rationale and use of shared resources should be described within the research plan. Applications requesting resources should include evaluations of the existing resources that are available to the PDs/PIs, but considered inadequate. Technology development should not be the primary goal of the Collaborative Grant Program.

Two tables are required and must be included within the page limit for the Research Program:

1. A table, organized by specific aims, that identifies the contributions expected from each PD/PI toward accomplishing that aim. For a truly integrated collaborative project, it is expected that most or all of the scientific aims will require substantial contributions from more than one PD/PI.
2. A table that identifies critical milestones and performance criteria, a timeline for completion, and whether critical milestones depend on the completion of antecedent milestones. Metrics for identifying successful completion of program aims and goals, and criteria for acceptable outcomes, should be defined. It is useful to identify interdependent steps with critical risks. Risk management and alternative approaches can be addressed elsewhere in the Research Strategy and can reference the table.

B. Team Management and Optional Activities: A "Multiple PD/PI Leadership Plan" is required as a separate attachment, and the information in that plan should not be duplicated here. This section should address:

• How the entire group will function to accomplish program objectives and vision,
• Strategies for building and maintaining group participation to develop collective intelligence, and
• Description of how credit will be shared.

The program management structure should avoid giving any single individual undue authority that prevents contributions from the wider team for setting program priorities, resource distribution, and reward. Strong team leadership with shared responsibilities is expected for complex teams to be successful. .

Applicants should develop a management structure based on project objectives that effectively promote the proposed research. The structure should account for team composition, institutional resources, and policies. NIGMS does not specify an organizational structure. Practical aspects should be described, including real time communication, intra-team data sharing, data archiving, and long-term preservation for team use.

Applications should describe management and decision-making processes that promote collective input for the overall project objectives and for oversight and reallocation of program resources. Plans should recognize that resources may need to be dynamically reallocated to achieve programmatic goals. Methods for attributing contributions to publications should be described to enable individual professional assessment in joint projects.

The overall management plan should include all key personnel, consultants, and other significant contributors, regardless of effort level. It is recommended that the Team Management Plan include procedures for evaluating scientific progress and overall support for program objectives of each of the PDs/PIs and key personnel, the changing need for PD/PI expertise to achieve program objectives, and the replacement of key personnel and PD(s)/PI(s) as needed, with the required prior approval for PD/PI changes.

The Team Management Plan should include a description of how the PD/PIs will establish and sustain a diverse and interdisciplinary team of researchers with an optimal range of backgrounds, expertise, and skills to successfully accomplish the goals of the program. There is evidence that teams employing complementary approaches and having diverse areas of intellectual and technical expertise are more productive if the process for making decisions incorporates different points of view. The Team Management Plan should describe how major disagreements will be resolved.

Programs may wish to appoint an External Advisory Committee (EAC) to provide advice and perspectives on progress and any major changes in project direction. If an EAC is to be appointed, its functions and operations should be described in this section. However, applicants should not identify any members in the application or contact potential candidates before the application has been reviewed. EACs are optional unless clinical research is proposed, in which case an EAC is required.

If future year developmental funds are requested to support additional ESI researchers, present plans for identifying, assessing, and evaluating relevant investigators. These should include:

• A plan for the solicitation of proposals, the review of their methodology and research performance, and prioritization and selection of the projects, as well as the role of the EAC in the process, if proposed.
• The plans for defining the scope of the research, limits on the dollars available, and the number of investigators and years of support per investigator.
• The eligibility criteria for the applicant pool. NIGMS does not require institutional affiliation of the ESIs with one of the initially participating institutions. Investigators must be ESIs and hold a faculty appointment or equivalent position when support from the award commences. For the purposes of this FOA, these must be individuals who can independently apply for Federal or non-Federal investigator-initiated peer-reviewed Research Project Grants (RPGs). Individuals holding postdoctoral fellowships or other positions that lack independent status are not eligible. ESIs supported with these developmental funds should not be appointed as a PD/PI and will retain their ESI status.
• Expectations of ESIs receiving developmental funds. Plans for evaluation of ESI mentoring, participation in team management, career development, interdisciplinary science training, overall productivity, and attainment of independent funding should be provided.

Research plans of specific ESIs should not be included in the application, only the process that will be used to select individuals who will receive support. Information about individuals and their research proposals must be submitted as prior approval requests in accordance with Section VI. 1. and must be approved by NIGMS before funds can be expended for this optional activity.

Other Plan(s):

Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H application forms packages.

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

• All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan.

Appendix:

Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

• No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.

PHS Human Subjects and Clinical Trials Information

When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.

PHS Assignment Request Form

All instructions in the SF424 (R&R) Application Guide must be followed.

3. Unique Entity Identifier and System for Award Management (SAM)

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times

Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time.  If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

Future year developmental funds for support of additional ESIs may only be used for that purpose, with NIGMS prior approval, and cannot be rebudgeted.

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and NIGMS. Applications that are incomplete or non-compliant will not be reviewed. 

Applications must include a PEDP submitted as an Other Attachment on the SF424(R&R) Other Project Information form. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn without review.

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in the policy

Section V. Application Review Information

1. Criteria

Only the review criteria described below will be considered in the review process.  Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

Note: Effective for due dates on or after January 25, 2023, the Data Sharing Plan and Genomic Data Sharing Plan (GDS) will not be evaluated at time of review.

A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Reviewers will consider each of the review criteria below in the determination of scientific merit and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by Center for Scientific Review, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications will receive a written critique.

Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.

Assignment of applications will be based on established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications. Following initial peer review, recommended applications will receive a second level of review by the National Advisory General Medical Sciences Council. The following will be considered in making funding decisions:

• Scientific and technical merit of the proposed project as determined by scientific peer review.
• Availability of funds.
• Relevance of the proposed project to program priorities.
• Portfolio balance.
• The ability of each PD/PI to devote a major part of their research effort to the team project.
• The extent of other research funding available to the PD/PIs, as per the NIGMS policies regarding investigators with substantial research support.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

Section VI. Award Administration Information

1. Award Notices

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the recipient's business official.

Recipients must comply with any funding restrictions described in Section IV.6. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website.  This includes any recent legislation and policy applicable to awards that is highlighted on this website.

Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.

ClinicalTrials.gov: If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain “applicable clinical trials” on the ClinicalTrials.gov Protocol Registration and Results System Information Website (https://register.clinicaltrials.gov). NIH expects registration and results reporting of all trials whether required under the law or not. For more information, see https://grants.nih.gov/policy/clinical-trials/reporting/index.htm

Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.

Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&R) and PHS 398).

Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).

Prior Approval for Use of Developmental Funds 

Research led by ESIs added to the program in YR2-5 will require prior approval by NIH prior to initiation of the work (see the NIH Grants Policy Statement 8.1.3 Requests for Prior Approval for instructions on submitting a request). While a change in scope is not permitted without re-review, additional approaches and expertise that take advantage of new opportunities and support the Collaborative Program are encouraged. The work should support the overall project goals, rather than the specific research plans of individual PD/PIs.

Prior to the commencement of any exploratory pilot studies, the following documentation must be submitted to NIGMS staff for administrative review six weeks before the requested start date, using PHS398 forms and instructions:

• Face page (signed by institutional signing official) 
• Project Summary (page 2) 
• Research Strategy section
• Research proposal (6 pages) should include an explanation of how the proposed work will be integrated into and enhance the overall goals of the Collaborative Program Award.
• Rigor and transparency: As appropriate, include a description of the scientific premise for the proposed project, including consideration of the strengths and weaknesses of published research or preliminary data crucial to the support of project, and a description of the experimental design and methods proposed and how the investigator will achieve robust and unbiased results. If applicable, also include a brief description of the methods to ensure the identity and validity of key biological and/or chemical resources used in the proposed project. See Notice NOT-OD-16-011 for details.
• Biographical sketch of lead investigator of pilot study and other key personnel. Pilot study PIs must not be added to the multi-PD/PI Leadership Plan for the overall collaborative program, and therefore, will retain their ESI status.
• External Advisory Committees (EAC) are optional unless clinical research is proposed. If proposed, the EAC is required and communication from the EAC chair (at a minimum) indicating that the EAC concurs with supporting the pilot studies must be included.
• If the proposed study involves human subjects, the following documents must be submitted to NIH: Plan addressing the risks and protections for human subjects, in accordance with NIH's Instructions for Preparing the Human Subjects Section of the Research Plan.
• Institutional Review Board (IRB) approval. 
• Human Subjects education certification.
• Create Inclusion Enrollment Record (IER) and enter inclusion data into the Human Subject System (HSS). 
• If the study involves Vertebrate Animal, Institutional Animal Care and Use Committee (IACUC) approval and the Vertebrate Animal Section must be submitted.

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General  and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities, including of note, but not limited to:

• Federalwide Research Terms and Conditions 
• Prohibition on Certain Telecommunications and Video Surveillance Services or Equipment 
• Acknowledgment of Federal Funding  

If a recipient is successful and receives a Notice of Award, in accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions. 

Should the applicant organization successfully compete for an award, recipients of federal financial assistance (FFA) from HHS will be required to complete an HHS Assurance of Compliance form (HHS 690) in which the recipient agrees, as a term and condition of receiving the grant, to  administer their programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, age, sex and disability, and agreeing to comply with federal conscience laws, where applicable.  This includes ensuring that entities take meaningful steps to provide meaningful access to persons with limited English proficiency; and ensuring effective communication with persons with disabilities. Where applicable, Title XI and Section 1557 prohibit discrimination on the basis of sexual orientation, and gender identity. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS.  Please see https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html and https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html 

HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.  For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. 

• Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency.  For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals see  https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html and https://www.lep.gov. 
• For information on an institution’s specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see  http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html. 
• HHS funded health and education programs must be administered in an environment free of sexual harassment, see https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see https://grants.nih.gov/grants/policy/harassment.htm.  
• For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws see  https://www.hhs.gov/conscience/conscience-protections/index.html and https://www.hhs.gov/conscience/religious-freedom/index.html.    

Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.html or call 1-800-368-1019 or TDD 1-800-537-7697.     

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 and 2 CFR Part 200.206 “Federal awarding agency review of risk posed by applicants.” This provision will apply to all NIH grants and cooperative agreements except fellowships.

Not Applicable

3. Data Management and Sharing

Note: The NIH Policy for Data Management and Sharing is effective for due dates on or after January 25, 2023.

Consistent with the NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the Data Management and Sharing requirements as outlined in the NIH Grants Policy Statement. Upon the approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described.

4. Reporting

When multiple years are involved, recipients will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.

A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement. NIH FOAs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 45 CFR Part 75.301 and 2 CFR Part 200.301.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for recipients of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later.  All recipients of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over the threshold.  See the NIH Grants Policy Statement for additional information on this reporting requirement.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and 2 CFR Part 200.113 and Appendix XII to 45 CFR Part 75 and 2 CFR Part 200, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period.  The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS).  This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313).  As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available.  Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 and 2 CFR Part 200 – Award Term and Condition for Recipient Integrity and Performance Matters.

5. Evaluation

In carrying out stewardship of grant programs, NIGMS will periodically evaluate the RM1 Collaborative Program Grant for Multidisciplinary Teams by employing the representative measures identified below. In assessing the effectiveness of research project grant investments, NIGMS may use information from progress reports and public databases, PD/PIs, and from participants themselves. Where necessary, PD/PIs and participants may be appropriately contacted after the completion of the grant period for updates on participants’ subsequent outcomes. The overall evaluation of the program will be based on metrics that may include, but are not limited to, the following: 

• Characteristics of the applicant and awardee pool for the program, such as: 
  • Geographic distribution 
  • Investigator demographics
  • Institution types
  • Scientific topics of supported research 
• Indicators of scientific accomplishments / productivity, such as: 
  • Peer-reviewed research publications and citations
  • Presentations at scientific conferences (talks, posters, etc.) 
  • Patent activity among grantees

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)

Finding Help Online: https://www.era.nih.gov/need-help (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Telephone: 301-480-7075

Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: support@grants.gov

Please direct all inquires to: RM1mailbox@nigms.nih.gov
 

James W. Mack, Ph.D.
Center for Scientific Review (CSR)
Email: mackj2@csr.nih.gov

Lisa Moeller
National Institute of General Medical Sciences (NIGMS)
Email: moellerl@mail.nih.gov

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75 and 2 CFR Part 200.